High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical

Kasper M Petersen1, Søren Bøgevig1, Troels Riis1

  • 1Department of Clinical Pharmacology Bispebjerg Hospital University of Copenhagen Copenhagen Denmark.

Insights

High-dose glucagon boluses significantly impact heart rate and blood pressure, irrespective of beta-blocker use. Glucagon infusion may be preferred over bolus for sustained hemodynamic effects in beta-blocker poisoning treatment.

Area of Science:

  • Cardiology
  • Clinical Pharmacology
  • Toxicology

Background:

  • High-dose intravenous glucagon is a recommended antidote for beta-blocker poisoning.
  • Clinical data on glucagon's hemodynamic effects and safety are limited.

Purpose of the Study:

  • To investigate the hemodynamic effects and safety of high-dose glucagon.
  • To compare glucagon's effects with and without concomitant beta-blockade.

Main Methods:

  • Randomized crossover study in 10 healthy men.
  • Administration of esmolol (beta-blocker) and/or glucagon (bolus or infusion) or saline placebo.
  • Monitoring of hemodynamic parameters and adverse effects.

Main Results:

  • Glucagon bolus significantly increased heart rate, systolic blood pressure, diastolic blood pressure, and cardiac output.
  • Hemodynamic effects were observed regardless of beta-blockade.
  • Nausea occurred in 80% of participants despite antiemetic pretreatment.

Conclusions:

  • High-dose glucagon boluses exert significant hemodynamic effects independent of beta-blockade.
  • Glucagon infusion demonstrated comparable and potentially longer-lasting effects than bolus administration.
  • Infusion may be a preferable administration method for glucagon in clinical practice.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
655
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
984
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
654
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
5.9K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
593